Company News 07 Sep 2022 Appointment of exclusive distributor of Remplir™ in Australia Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia. Orthocell
Media, Video 22 Jul 2022 VIDEO | Proactive Investors – July 2022 Orthocell’s Paul Anderson spoke with Alisha Newell at Proactive Investors to discuss the Company’s strong position following the recently executed… Orthocell
Media 22 Jul 2022 Dr Boreham’s Crucible | July 2022 Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist,… Orthocell
Media, Video 08 Jul 2022 VIDEO | ShareCafe ‘Hidden Gems’ Webinar – July 2022 Orthocell CEO and Managing Director, Paul Anderson, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar. Orthocell
Company News 27 Jun 2022 Striate+â„¢ global exclusive license and manufacturing agreement with BioHorizons Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+â„¢, with BioHorizons Implant… Orthocell
Media, Video 12 May 2022 Remplirâ„¢ Channel 7 News feature Clinical trial participant Damian Hall was featured in a national news story by Channel 7 News Reporter, Alison Fan, to… Orthocell
Company News 29 Apr 2022 Quarterly Report | Period To 31 March 2022 Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include:… Orthocell
Media, Video 22 Mar 2022 VIDEO | Proactive Investors – March 2022 Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in… Orthocell
Company News 21 Mar 2022 TGA Approval for Remplir™ Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval. Orthocell
Company News 28 Feb 2022 Striate+™ Market Update Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum. Orthocell
